Press Releases

January 31, 2023

 

Oculis CEO Riad Sherif MD to Participate in Glaucoma 360 New Horizons Forum
 

January 5, 2023

 

Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in Diabetic Macular Edema (DME)
 

November 22, 2022

 

Oculis announces publication of positive Phase 2 data in Translational Vision Science & Technology investigating topical anti-TNFα agent Licaminlimab (OCS-02) in acute anterior uveitis
 

November 3, 2022

 

Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development
 

October 17, 2022

 

Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company
 

September 6, 2022

 

Oculis announces publication of Phase 2 data showing topical OCS-01 improves macular thickness and VA in patients with DME
 

August 23, 2022

 

Oculis announces publication of Ph2 data showing topical anti-TNFα agent licaminlimab OCS-02 relieves ocular discomfort in DED

June 29, 2022

 

First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 for Inflammation and Pain following Cataract Surgery

March 2, 2022

 

Oculis Strengthens Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma

February 8, 2022

 

Oculis appoints Dr. Bastian Dehmel as Chief Development Officer

January 5, 2022

 

Oculis appoints Mr. Webb Ding as Global COO and GM China